Financial burden and quality of life of informal caregivers of patients with wet age-related macular degeneration
Open accessThe DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Abstract
PURPOSE: The purpose of this research is to quantify the cost burden, care times and the impact on the quality of life (QoL) of informal caring relatives caring for patients with wet age-related macular degeneration (wet AMD). Moreover we investigated the impact of care times on the QoL. METHODS: Through a specifically designed questionnaire, 150 caring relatives were interviewed retrospectively on all accrued financial costs, caring times incurred and the current QoL, assessed by a Visual Analogue Scale for happiness (VAS). RESULTS: The caring time incurred was on average 6.4 ± 8.5 (mean +/- SD) hours per week. The QoL was on average rated at 6.7 ± 1.9 on a ten point scale. Financial strain was incurred by the direct non-medical costs of on average € 405 ± 1104 and the direct medical costs of on average € 134 ± 340 per year. Indirect costs were stated by two caregivers as amounting to € 2400 and € 6000 net income loss per year respectively. Caregivers of privately insured patients with wet AMD carried a financial cost burden which was up to six times higher than caregivers of patients who were on state insurance while showing the same visual acuity. CONCLUSION: The evaluation shows that caregivers of privately insured patients with wet AMD have higher costs than caregivers of patients with state insurance coverage. This burden seems to be a factor to be considered independently since it does not appear to have any relation to patients AMD acuity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures





Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Nine studies [34, 37–43, 45] reported direct non-medical costs per patient per annum, ranging from $688 to $15,418 (Fig. 3).”
From The economic impact of retinal diseases for which gene therapy is emerging: a systematic literature review (2025) · cites this paper as [37]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The most frequent resources accounted for within direct non-medical costs were formal care [34, 38–43, 45] and assistive technologies [34, 37–39, 41–43, 45], followed by transportation [34, 37–39, 42, 45] and subsidies [40–43] (Table 3).”
From The economic impact of retinal diseases for which gene therapy is emerging: a systematic literature review (2025) · cites this paper as [37]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Additionally, annual productivity loss in carers was estimated at $95.12 in one German study [37].”
From The economic impact of retinal diseases for which gene therapy is emerging: a systematic literature review (2025) · cites this paper as [37]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“While annual direct non-medical costs were uniformly lower than direct medical costs in three studies [34, 39, 40] reporting both types of costs, they were higher in other cases [37, 41–43, 45].”
From The economic impact of retinal diseases for which gene therapy is emerging: a systematic literature review (2025) · cites this paper as [37]
The cited source says what the claim attributes to it.
In the citing paper
“Of note, two retrospective studies [37, 39] qualitatively noted a minority of subjects (patients or carers) experiencing productivity loss.”
From The economic impact of retinal diseases for which gene therapy is emerging: a systematic literature review (2025) · cites this paper as [37]
4 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ranibizumab for Neovascular Age-Related Macular Degeneration
Rosenfeld, P. J., Brown, D. M., Heier, J. S., Boyer, D. S., Kaiser, P. K., Chung, C. Y., & Kim, R. Y. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa054481 · Cited by 5,886
Risk factors for age-related macular degeneration
Smith, W., Assink, J., Klein, R., Mitchell, P., Klaver, C. C. W., Klein, B. E. K., Hofman, A., Jensen, S., Wang, J. J., & de Jong, P. T. V. M. (2001) · Ophthalmology · doi:10.1016/s0161-6420(00)00580-7 · Cited by 1,071 · cited 1×
“Epidemiological studies in AMD were able to provide information on the prevalence of the condition and demonstrate a six-fold risk of developing AMD at the age of 70–79, growing to 25-fold in persons over 80 in comparison to the 55–69 age group [2].”
BackgroundBrouwer, W. B. F., van Exel, N. J. A., van Gorp, B., & Redekop, W. K. (2006) · Quality of Life Research · doi:10.1007/s11136-005-5994-6 · Cited by 452 · cited 1×
“It facilitates surveying the impact on caregivers’ QoL [13].”
BackgroundNijboer, C., Triemstra, M., Tempelaar, R., Sanderman, R., & van den Bos, G. A. M. (1999) · Social Science & Medicine · doi:10.1016/s0277-9536(98)00426-2 · Cited by 276
Influence of age-related maculopathy on visual functioning and health-related quality of life
Mangione, C. M., Gutierrez, P. R., Lowe, G., Orav, E. J., & Seddon, J. M. (1999) · American Journal of Ophthalmology · doi:10.1016/s0002-9394(99)00169-5 · Cited by 255
Nijboer, Triemstra, M., Tempelaar, & Sanderman (1999) · Social Science & Medicine · Cited by 209
Association between Vision Loss and Higher Medical Care Costs in Medicare Beneficiaries
Javitt, J. C., Zhou, Z., & Willke, R. J. (2007) · Ophthalmology · doi:10.1016/j.ophtha.2006.07.054 · Cited by 154 · cited 3×
“Javitt JC, Zhou Z, Willke RJ. Association between vision loss and higher medical care costs in Medicare beneficiaries costs are greater for those with progressive vision loss.”
BackgroundThe Impact of Age-Related Macular Degeneration on Health Status Utility Values
Espallargues, M., Czoski-Murray, C. J., Bansback, N. J., Carlton, J., Lewis, G. M., Hughes, L. A., Brand, C. S., & Brazier, J. E. (2005) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.05-0072 · Cited by 150
The Impact of Vision Impairment on Vision-Specific Quality of Life in Germany
Finger, R. P., Fenwick, E., Marella, M., Dirani, M., Holz, F. G., Chiang, P. P.-C., & Lamoureux, E. L. (2011) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.10-7127 · Cited by 114
Vision-Specific Quality-of-Life Research: A Need to Improve the Quality
Lamoureux, E. L., & Pesudovs, K. (2011) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2010.09.020 · Cited by 114
Cited by
The economics of vision impairment and its leading causes: A systematic review
Marques, A. P., Ramke, J., Cairns, J., Butt, T., Zhang, J. H., Jones, I., Jovic, M., Nandakumar, A., Faal, H., Taylor, H., et al. (2022) · eClinicalMedicine · doi:10.1016/j.eclinm.2022.101354 · Cited by 137
Hanemoto, T., Hikichi, Y., Kikuchi, N., & Kozawa, T. (2017) · PLoS ONE · doi:10.1371/journal.pone.0189035 · Cited by 42
Economic Burden of Late-Stage Age-Related Macular Degeneration in Bulgaria, Germany, and the US
Paudel, N., Brady, L., Stratieva, P., Galvin, O., Lui, B., Brande, I. V. D., Malkowski, J., Rebeira, M., MacAllister, S., O’Riordan, T., et al. (2024) · JAMA Ophthalmology · doi:10.1001/jamaophthalmol.2024.4401 · Cited by 44
Torres, G. C. S., Sumile, E. F., Rebueno, M. C. D. R., Parial, L. L., Malong‐Consolacion, C. P., Estrada, M. G., Macindo, J. R. B., & Hendrix, C. C. (2021) · Nursing Forum · doi:10.1111/nuf.12618 · Cited by 18
The Challenges of Treating Neovascular Age-Related Macular Degeneration
Hollaus, M., Buehl, W., Schmidt-Erfurth, U. M., & Sacu, S. (2021) · Klinische Monatsblätter für Augenheilkunde · doi:10.1055/a-1473-5713 · Cited by 17
“Besides the time and financial burden, relatives reported that caregiving was associated with a subjective burden and reduced quality of life [31, 32].”
Background
Metadata
- Authors
- Weyer-Wendl, H., & Walter, P.
- Affiliations
- RWTH Aachen University (DE)
- Corresponding author
- Weyer-Wendl, Hannah
- ORCID
- Walter, Peter
- Venue
- Health Economics Review
- Published
- 2016-08-26
- Volume
- 6
- Issue
- 1
- Pages
- 37-37
- ISSN
- 2191-1991 (ISSN-L)
- PMC
- PMC4999382
- OpenAlex
- W2515090491
- Cited by
- 11
- References
- 19
- Citations by year
- 2025: 2 · 2024: 2 · 2022: 1 · 2021: 3 · 2020: 1 · 2017: 1 · 2016: 1
- FWCI
- 0.71
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- Locations
- Health Economics Review (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Econstor (Econstor) (submittedVersion, cc-by)
- RWTH Publications (RWTH Aachen) (submittedVersion, cc-by)
- RWTH Publications (RWTH Aachen)
- Funders
- RWTH Aachen University
- Topics
- Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
- Health Sciences › Nursing › Research and Theory › Nursing care and research
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Health Systems, Economic Evaluations, Quality of Life
- Keywords
- neovascular age-related macular degeneration, informal caregivers, caregiver financial burden, quality of life, care time, indirect costs, income loss, private health insurance, state health insurance, visual acuity
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Financial burden and quality of life of informal caregivers of patients with wet age-related macular degeneration. https://app.cochat.ai/papers/10.1186/s13561-016-0116-4
- The paper
- Weyer-Wendl, H., & Walter, P. (2016). Financial burden and quality of life of informal caregivers of patients with wet age-related macular degeneration. Health Economics Review. https://doi.org/10.1186/s13561-016-0116-4
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.